LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Operating Income
Profit from core operations after operating expenses, before interest and taxes.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$44.14M, compared with -$16.93M a year earlier. Trailing-twelve-month operating income was -$118.34M.
Context
- Operating income amounted to 477.5% of revenue in FY2025.
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 5 analysts of -$116.31M (-27.6%) for the fiscal year ending Dec 2026, a step up from the -55.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$44.14M-14.7% QoQ
- Last fiscal yearDec 2025
- -$91.14M-55.5% YoY
- LTMMar 2026
- -$118.34M-99.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -160.7% | -95.8% | +64.9 pp |
| 1 year | -55.5% | -27.6% | +27.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (91.14M) USD
- Year-over-year change
- -55.5%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (91.14M) | -55.5% |
| FY2024 | 2024-12-31 | (58.61M) | +19.1% |
| FY2023 | 2023-12-31 | (72.43M) | -590.9% |
| FY2022 | 2022-12-31 | (10.48M) | +82.7% |
| FY2021 | 2021-12-31 | (60.44M) | — |
Operating Income vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -99.1% is the 10th highest of 11, against a peer median of -6.6%.
- Operating income amounts to 563.8% of revenue for LENZ, versus a peer median of 63.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $154.67M USD | +268.8% | — | 80.8% | |
| LTM Jun 2026 | $96.09M USD | +129.8% | — | 46.0% | |
| FY2025 | -€10.82M EUR | +84.2% | — | 36.5% | |
| LTM Mar 2026 | -$37.37M USD | +72.2% | — | 19.1% | |
| LTM Mar 2026 | -$66.69M USD | -29.4% | — | — | |
| LTM Mar 2026 | -$87.25M USD | -13.1% | — | — | |
| LTM Mar 2026 | -$118.34M USD | -99.1% | — | 563.8% | |
| LTM Mar 2026 | -$134.12M USD | -22.9% | — | — | |
| LTM Mar 2026 | -$142.91M USD | -25.7% | — | — | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | -$202.42M USD | -647.8% | — | 204.5% |
| LTM Mar 2026 | -$206.61M USD | -0.0% | — | 5121.8% | |
| Peer median (excluding LENZ) | — | -6.6% | — | 63.4% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| Weighted Avg Shares | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
| Weighted Avg Shares (Diluted) | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.